Actively Recruiting
Baseline Atrial Fibrosis Predicts Risk for Post-operative Atrial Fibrillation in Patients Undergoing Cardiac Surgery
Led by Tulane University · Updated on 2026-03-05
50
Participants Needed
3
Research Sites
244 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study aims to evaluate and compare the incidence of atrial arrhythmias (including Post-Operative Atrial Fibrillation (POAF), atrial flutter, and atrial tachycardia) stratified by baseline Utah fibrosis stages and overall fibrosis (%) of the left atrial wall area. The investigators hypothesize that patients with a higher baseline Utah fibrosis staging will experience a higher incidence of POAF. The study also aims to evaluate and compare the in-hospital mortality, length-of-stay (LOS), complication rates (strokes, pneumonia, respiratory failure etc.) of the different Utah fibrosis stage cohorts. Perform cost analysis and compare between patients with POAF and patients without POAF. The investigators hypothesize that patients experiencing POAF will have a higher mortality rate, longer LOS, greater complications, and therefore, additional hospital costs.
CONDITIONS
Official Title
Baseline Atrial Fibrosis Predicts Risk for Post-operative Atrial Fibrillation in Patients Undergoing Cardiac Surgery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female patients age 40 years of age or older
- Patients with no history of atrial arrhythmia (atrial fibrillation, atrial flutter, atrial tachycardia) scheduled to undergo cardiac surgery, including coronary artery bypass graft (CABG), valvular repair/reconstruction, aneurysm repair, or pacemaker insertion
You will not qualify if you...
- Patients with a history of atrial arrhythmia (atrial fibrillation, atrial flutter, atrial tachycardia)
- Patients with a history of cardiac or open chest surgery
- Patients with a history of catheter ablation
- Patients under the age of 40
- Patients with left ventricular assist device (LVAD) or scheduled to have LVAD implanted
- Patients who have previously undergone extracorporeal membrane oxygenation (ECMO)
- Patients who have undergone or will undergo heart transplantation
- Patients with any health related Late Gadolinium Enhancement (LGE)-MRI contraindications, including allergic reaction to gadolinium or implanted devices contraindicated for MRI
- Patients with severe acute or chronic renal disease with a low glomerular filtration rate (GFR) less than 30 mL/min/1.73 m2
- Patients weighing more than 300 lbs
- Patients currently pregnant or breastfeeding, or planning pregnancy during the study
- Patients with cognitive impairment preventing informed consent
- Patients who cannot read, speak, or understand English
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Lakeview Hospital
Covington, Louisiana, United States, 70433
Actively Recruiting
2
East Jefferson General Hospital
New Orleans, Louisiana, United States, 70006
Actively Recruiting
3
Washington University Barnes-Jewish Hospital
St Louis, Missouri, United States, 63110
Actively Recruiting
Research Team
Y
Yara Menassa, MD
CONTACT
K
Kunal Sameer, MD, MHA
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here